FOLD Stock Risk & Deep Value Analysis
Amicus Therapeutics Inc
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About FOLD Stock
We analyzed Amicus Therapeutics Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran FOLD through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Not Applicable. Here's what we found.
FOLD Risk Analysis & Red Flags
What Could Go Wrong
For a current investor holding FOLD shares, nothing further can go 'wrong' as the acquisition is complete and shares were converted to cash at $14.50. For new investors, there is no opportunity for investment.
Risk Matrix
Overall
Not Applicable
Financial
Not Applicable
Market
Not Applicable
Competitive
Not Applicable
Execution
Not Applicable
Regulatory
Not Applicable
Red Flags
- ⚠
Company was acquired by BioMarin Pharmaceutical on April 27, 2026.
- ⚠
Common stock was delisted from Nasdaq on April 28, 2026.
- ⚠
No longer an independent publicly traded entity.
Upcoming Risk Events
- 📅
Not applicable; Amicus is no longer a standalone entity.
When to Reconsider
- 🚪
Not applicable; shares are no longer traded.
Unlock FOLD Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Amicus Therapeutics Inc (FOLD) Do?
Market Cap
$4.55B
Sector
Healthcare
Industry
Biotechnology
Employees
499
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company's commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, a novel two-component treatment program for adults living with late-onset Pompe disease. It has collaboration and license agreement with GlaxoSmithKline to develop and commercialize Galafold. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.
Visit Amicus Therapeutics Inc WebsiteInvestment Thesis
There is no investment thesis for Amicus Therapeutics (FOLD) as it has been acquired by BioMarin Pharmaceutical and delisted. The company no longer exists as an independent public equity investment opportunity.
Is FOLD Stock Undervalued?
Unlock the full AI analysis for FOLD
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
FOLD Price Targets & Strategy
12-Month Target
$0.00
Bull Case
$0.00
Bear Case
$0.00
Valuation Basis
Amicus Therapeutics (FOLD) was acquired for $14.50 per share cash on April 27, 2026, and subsequently delisted. Shares are no longer publicly traded, thus no future price target is applicable for an independent entity.
Entry Strategy
Not applicable; FOLD is no longer a publicly traded stock.
Exit Strategy
Not applicable; FOLD is no longer a publicly traded stock. Shares were converted to cash at $14.50.
Portfolio Allocation
0% (Not applicable; FOLD is no longer a publicly traded stock.)
Price Targets & Strategy
Sign up free to unlock price targets and entry/exit strategies
Is FOLD Financially Healthy?
Valuation
Forward P/E
45.91
Profitability
Gross Margin
88.50%
Operating Margin
5.17%
Net Margin
-4.27%
Return on Equity
-12.02%
Revenue Growth
20.05%
EPS
$-0.09
Balance Sheet
Current Ratio
2.84
Quick Ratio
1.72
Debt/Equity
1.43
Other
Beta (Volatility)
-0.40
Does FOLD Have a Competitive Moat?
Sign in to unlockMoat Rating
⚪ None
Moat Trend
Not Applicable
Moat Sources
1 Identified
The independent moat of Amicus Therapeutics ceased to exist upon its acquisition by BioMarin, as its assets and competitive positioning are now part of a larger corporate structure.
Moat Erosion Risks
- •Not applicable; the primary risk for Amicus's moat was acquisition, which has occurred.
FOLD Competitive Moat Analysis
Sign up to see competitive advantages
FOLD Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Not Applicable (No independent social sentiment for a delisted stock.)
Institutional Sentiment
Not Applicable (No independent institutional sentiment for a delisted stock.)
Insider Activity (Form 4)
No specific Form 4 insider purchase/sale details were found in the last 90 days. Insider activity for FOLD as a standalone entity ceased upon acquisition.
Options Flow
Not Applicable (No options trading for a delisted stock.)
Earnings Intelligence
Next Earnings
Not applicable (Amicus is no longer a standalone reporting issuer).
Surprise Probability
Not Applicable
Historical Earnings Pattern
Not applicable.
Key Metrics to Watch
Competitive Position
Top Competitor
Not Applicable (Amicus is no longer a standalone competitor).
Market Share Trend
Not Applicable (Amicus is no longer a standalone entity.)
Valuation vs Peers
Not Applicable (Amicus is no longer publicly traded.)
Competitive Advantages
- •Not applicable; Amicus's former competitive advantages are now integrated into BioMarin.
Market Intelligence
Sign up free to unlock sentiment, earnings intel, and peer analysis
What Could Drive FOLD Stock Higher?
Near-Term (0-6 months)
- •Not applicable; Amicus is no longer a standalone entity.
Medium-Term (6-18 months)
- •Not applicable; Amicus is no longer a standalone entity.
Long-Term (18+ months)
- •Not applicable; Amicus is no longer a standalone entity.
Catalysts & Growth Drivers
Sign up free to see growth catalysts
What's the Bull Case for FOLD?
- ✓
Not applicable; FOLD is no longer investable.
Bull Case Analysis
Sign up free to see the bull case
Competing with FOLD
See how Amicus Therapeutics Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Amicus Therapeutics Inc FOLD | $4.5B | 0.1 | — | $571.2M | -4.3% | 20.1% | |
AbbVie Inc ABBV | $381.1B | 0.1 | 104.8 | $15.0B | 5.8% | 9.5% | Compare → |
Johnson & Johnson JNJ | $557.1B | 1.0 | 26.5 | — | 21.8% | 7.9% | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $146.4B | 4.0 | 19.5 | $62.6B | 11.8% | 1.4% | Compare → |
UnitedHealth Group Inc UNH | $365.5B | 0.3 | 30.3 | $447.6B | 2.7% | 9.7% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Amicus Therapeutics Inc Makes Money
Prior to its acquisition by BioMarin, Amicus Therapeutics was a global biotechnology company focused on developing and commercializing innovative medicines for rare diseases. Its primary revenue came from Galafold, a precision medicine for Fabry disease, and it was developing next-generation Pompe disease therapies like Pombiliti and Opfolda. Its business model involved drug discovery, clinical development, regulatory approval, and commercialization within niche rare disease markets.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Amicus Therapeutics Inc (FOLD)?
As of May 16, 2026, Amicus Therapeutics Inc has a DVR Score of 0.1 out of 10, placing it in the "Distressed" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Amicus Therapeutics Inc?
Amicus Therapeutics Inc's market capitalization is approximately $4.5B. The company operates in the Healthcare sector within the Biotechnology industry.
What ticker symbol does Amicus Therapeutics Inc use?
FOLD is the ticker symbol for Amicus Therapeutics Inc. The company trades on the NGM.
What is the risk level for FOLD stock?
Our analysis rates Amicus Therapeutics Inc's overall risk as Not Applicable. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
Is Amicus Therapeutics Inc's revenue growing?
Amicus Therapeutics Inc has reported revenue growth of 20.1%. The company is showing strong top-line momentum.
Is FOLD stock profitable?
Amicus Therapeutics Inc has a profit margin of -4.3%. The company is currently unprofitable.
How often is the FOLD DVR analysis updated?
Our AI-powered analysis of Amicus Therapeutics Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on May 16, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for FOLD (Amicus Therapeutics Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.